Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Ahn, Brian ^a   Kohanbash, Gary ^a   Ohkuri, Takayuki ^a   Kosaka, Akemi ^a   Chen, Xiaowei ^b   Ikeura, Maki ^a   Wang, Timothy C ^c   Okada, Hideho ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

^c NONE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

glioma; histamine; histidine decarboxylase; myeloid cells; prostaglandin E2

Indexed keywords

CD11B ANTIGEN; CELECOXIB; GREEN FLUORESCENT PROTEIN; HISTAMINE; HISTIDINE DECARBOXYLASE; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BRAIN INFILTRATING LEUKOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CELL ISOLATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GLIOMA; IMMUNE DEFICIENCY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84941779434     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1047581     Document Type: Article

References (38)

1. E.Linos, T.Raine, A.Alonso, D.Michaud. Atopy and Risk of Brain Tumors: A Meta-analysis. J Natl Cancer Inst 2007; 99:1544-50; PMID:17925535; http://dx.doi.org/10.1093/jnci/djm170
2. J.L.Wiemels, J.K.Wiencke, J.D.Sison, R.Miike, A.McMillan, M.Wrensch. History of allergies among adults with glioma and controls. Int J Cancer 2002; 98:609-15; PMID:11920623; http://dx.doi.org/10.1002/ijc.10239
3. H.Wang, T.L.Diepgen. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005; 60:1098-111; PMID:16076292; http://dx.doi.org/10.1111/j.1398-9995.2005.00813.x
4. M.E.Scheurer, E.S.Amirian, S.L.Davlin, T.Rice, M.Wrensch, M.L.Bondy. Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int J Cancer 2011; 129:2290-6; PMID:21190193; http://dx.doi.org/10.1002/ijc.25883
5. M.E.Scheurer, R.El-Zein, P.A.Thompson, K.D.Aldape, V.A.Levin, M.R.Gilbert, J.S.Weinberg, M.L.Bondy. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev 2008; 17:1277-81; PMID:18483351; http://dx.doi.org/10.1158/1055-9965.EPI-07-2621
6. T.C.van der Pouw Kraan, A.Snijders, L.C.Boeije, E.R.de Groot, A.E.Alewijnse, R.Leurs, L.A.Aarden. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Investig 1998; 102:1866-73; PMID:9819373; http://dx.doi.org/10.1172/JCI3692
7. R.Colucci, J.V.Fleming, R.Xavier, T.C.Wang. L-histidine decarboxylase decreases its own transcription through downregulation of ERK activity. Am J Physiol Gastrointest Liver Physiol 2001; 281:G1081-91; PMID:11557529
8. X.D.Yang, W.Ai, S.Asfaha, G.Bhagat, R.A.Friedman, G.Jin, H.Park, B.Shykind, T.G.Diacovo, A.Falus et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med 2011; 17:87-95; PMID:21170045; http://dx.doi.org/10.1038/nm.2278
9. J.Schmielau, O.J.Finn. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001; 61:4756-60; PMID:11406548
10. C.Y.Liu, Y.M.Wang, C.L.Wang, P.H.Feng, H.W.Ko, Y.H.Liu, Y.C.Wu, Y.Chu, F.T.Chung, C.H.Kuo et al. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33 + myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136:35-45; PMID:19572148; http://dx.doi.org/10.1007/s00432-009-0634-0
11. A.H.Zea, P.C.Rodriguez, M.B.Atkins, C.Hernandez, S.Signoretti, J.Zabaleta, D.McDermott, D.Quiceno, A.Youmans, A.O'Neill, J.Mier et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8; PMID:15833831
12. T.Condamine, D.I.Gabrilovich. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32:19-25; PMID:21067974; http://dx.doi.org/10.1016/j.it.2010.10.002
13. D.I.Gabrilovich, S.Ostrand-Rosenberg, V.Bronte. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
14. M.Fujita, G.Kohanbash, W.Fellows-Mayle, R.L.Hamilton, Y.Komohara, S.A.Decker, J.R.Ohlfest, H.Okada. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71:2664-74; PMID:21324923; http://dx.doi.org/10.1158/0008-5472.CAN-10-3055
15. G.Kohanbash, K.McKaveney, M.Sakaki, R.Ueda, A.H.Mintz, N.Amankulor, M.Fujita, J.R.Ohlfest, H.Okada. GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-alpha. Cancer Res 2013; 73:6413-23; PMID:24030977; http://dx.doi.org/10.1158/0008-5472.CAN-12-4124
16. H.Ohtsu, S.Tanaka, T.Terui, Y.Hori, Y.Makabe-Kobayashi, G.Pejler, E.Tchougounova, L.Hellman, M.Gertsenstein, N.Hirasawa et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett 2001; 502:53-6; PMID:11478947; http://dx.doi.org/10.1016/S0014-5793(01)02663-1
17. I.Yang, T.Tihan, S.J.Han, M.R.Wrensch, J.Wiencke, M.E.Sughrue, A.T.Parsa. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 2010; 17:1381-5; PMID:20727764; http://dx.doi.org/10.1016/j.jocn.2010.03.031
18. M.Bencsath, J.Gidali, J.Szeberenyi, G.Veszely, K.Hegyi, A.Falus. Regulation of murine hematopoietic colony formation by histamine. Inflamm Res 2000; 49 Suppl 1:S66-7; PMID:10864426; http://dx.doi.org/10.1007/PL00000187
19. X.D.Yang, W.Ai, S.Asfaha, G.Bhagat, R.A.Friedman, G.Jin, H.Park, B.Shykind, T.G.Diacovo, A.Falus et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med 2011; 17:87-95; PMID:21170045; http://dx.doi.org/10.1038/nm.2278
20. B.Raychaudhuri, P.Rayman, J.Ireland, J.Ko, B.Rini, E.C.Borden, J.Garcia, M.A.Vogelbaum, J.Finke. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncol 2011; 13:591-9; PMID:21636707; http://dx.doi.org/10.1093/neuonc/nor042
21. E.Peranzoni, S.Zilio, I.Marigo, L.Dolcetti, P.Zanovello, S.Mandruzzato, V.Bronte. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-44; PMID:20171075; http://dx.doi.org/10.1016/j.coi.2010.01.021
22. M.K.Srivastava, P.Sinha, V.K.Clements, P.Rodriguez, S.Ostrand-Rosenberg. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70:68-77; PMID:20028852; http://dx.doi.org/10.1158/0008-5472.CAN-09-2587
23. J.-I.Youn, D.I.Gabrilovich. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-75; PMID:21061430; http://dx.doi.org/10.1002/eji.201040895
24. S.L.Highfill, P.C.Rodriguez, Q.Zhou, C.A.Goetz, B.H.Koehn, R.Veenstra, P.A.Taylor, A.Panoskaltsis-Mortari, J.S.Serody, D.H.Munn et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–dependent mechanism that is up-regulated by interleukin-13. Blood 2010; 116:5738-47; PMID:20807889; http://dx.doi.org/10.1182/blood-2010-06-287839
25. M.Dy, E.Schneider. Histamine-cytokine connection in immunity and hematopoiesis. Cytokine Growth Factor Rev 2004; 15:393-410; PMID:15450254; http://dx.doi.org/10.1016/j.cytogfr.2004.06.003
26. C.E.Rolle, S.Sengupta, M.S.Lesniak. Mechanisms of immune evasion by gliomas. Adv Exp Med Biol 2012; 746:53-76; PMID:22639159; http://dx.doi.org/10.1007/978-1-4614-3146-6_5
27. M.E.Sughrue, I.Yang, A.J.Kane, M.J.Rutkowski, S.Fang, C.D.James, A.T.Parsa. Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med 2009; 7:84; PMID:19814820; http://dx.doi.org/10.1186/1479-5876-7-84
28. M.Hirohata, Y.Sasaguri, M.Shigemori, H.Maruiwa, M.Morimatsu. A role for histamine in human-malignant glioma-cells. Int J Oncol 1995; 7:1109-15; PMID:21552939
29. A.M.Asemissen, C.Scheibenbogen, A.Letsch, K.Hellstrand, F.Thoren, K.Gehlsen, A.Schmittel, E.Thiel, U.Keilholz. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). Clin Cancer Res 2005; 11:290-7; PMID:15671558
30. M.Brune, S.Castaigne, J.Catalano, K.Gehlsen, A.D.Ho, W.K.Hofmann, D.E.Hogge, B.Nilsson, R.Or, A.I.Romero et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006; 108:88-96; PMID:16556892; http://dx.doi.org/10.1182/blood-2005-10-4073
31. A.C.Ochoa, A.H.Zea, C.Hernandez, P.C.Rodriguez. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. ClinCancer Res 2007; 13:721s-6s; PMID:17255300
32. W.Park, Y.Oh, J.Han, H.Pyo. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2. J Exp Cli Cancer Res 2008; 27:66; PMID:19000324; http://dx.doi.org/10.1186/1756-9966-27-66
33. M.Jutel, T.Watanabe, S.Klunker, M.Akdis, O.A.Thomet, J.Malolepszy, T.Zak-Nejmark, R.Koga, T.Kobayashi, K.Blaser et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413:420-5; PMID:11574888; http://dx.doi.org/10.1038/35096564
34. R.Noubade, G.Milligan, J.F.Zachary, E.P.Blankenhorn, R.del Rio, M.Rincon, C.Teuscher. Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice. J Clin Invest 2007; 117:3507-18; PMID:17965772; http://dx.doi.org/10.1172/JCI32792
35. B.Vanbervliet, M.Akdis, M.Vocanson, A.Rozieres, J.Benetiere, P.Rouzaire, C.A.Akdis, J.F.Nicolas, A.Hennino. Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-gamma/IL-17 balance in T cell-mediated skin inflammation. J Allergy Clin Immunol 2011; 127:943–53 e1-10; PMID:21269673; http://dx.doi.org/10.1016/j.jaci.2010.12.002
36. M.Fujita, M.E.Scheurer, S.A.Decker, H.A.McDonald, G.Kohanbash, E.R.Kastenhuber, H.Kato, M.L.Bondy, J.R.Ohlfest, H.Okada. Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 2010; 16:3409-19; PMID:20472682; http://dx.doi.org/10.1158/1078-0432.CCR-10-0644
37. S.M.Wiesner, S.A.Decker, J.D.Larson, K.Ericson, C.Forster, J.L.Gallardo, C.Long, Z.L.Demorest, E.A.Zamora, W.C.Low et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res 2009; 69:431-9; PMID:19147555; http://dx.doi.org/10.1158/0008-5472.CAN-08-1800
38. M.Fujita, X.Zhu, R.Ueda, K.Sasaki, G.Kohanbash, E.R.Kastenhuber, H.A.McDonald, G.A.Gibson, S.C.Watkins, R.Muthuswamy et al. Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells–Significant Roles of CXCL10. Cancer Res 2009; 69:1587-95; PMID:19190335; http://dx.doi.org/10.1158/0008-5472.CAN-08-2915